Entasis Therapeutics to Participate in the Cantor Fitzgerald Virtual Global Healthcare Conference

Rhea-AI Summary

Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX) announced its participation in the Cantor Fitzgerald Virtual Global Healthcare Conference from September 27-30, 2021. The company will present on September 30 at 1:20 p.m. EDT, featuring a company presentation and one-on-one investor meetings. A webcast of the presentation can be accessed on the company’s website. Entasis focuses on developing novel antibacterial products targeting serious infections caused by multidrug-resistant Gram-negative bacteria, with a pipeline that includes key candidates like sulbactam-durlobactam and zoliflodacin.

WALTHAM, Mass., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today that management will participate in the upcoming Cantor Fitzgerald Virtual Global Healthcare Conference to be held September 27-30, 2021.

Details of the Company’s participation can be found below:

	Cantor Fitzgerald Virtual Global Healthcare Conference
	Format: Company presentation and one-on-one investor meetings
	Date: Thursday September 30, 2021
	Time: 1:20 p.m. EDT
	Webcast: https://wsw.com/webcast/cantor12/ettx/2120370

The webcast of the Company’s presentation will be accessible in the News & Events section of the Entasis website at https://www.entasistx.com/.

About Entasis
Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis’ pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0462 (targeting multiple Gram-negative pathogens including Pseudomonas aeruginosa) and ETX0282CPDP (targeting Enterobacteriaceae infections). For more information, visit www.entasistx.com.

Entasis Contacts         
Company:
Kyle Dow
Entasis Therapeutics
(781) 810-0114
kyle.dow@entasistx.com 

Investor Relations:
Bruce Mackle
LifeSci Advisors
(929) 469-3859
bmackle@lifesciadvisors.com 

FAQ

What is the date for Entasis Therapeutics' presentation at the Cantor Fitzgerald Conference?

Entasis Therapeutics will present on September 30, 2021, at 1:20 p.m. EDT.

How can I access the webcast of Entasis Therapeutics' presentation?

The webcast can be accessed via the company’s website during the presentation.

What is the focus of Entasis Therapeutics?

Entasis Therapeutics is focused on developing antibacterial products for serious infections caused by multidrug-resistant Gram-negative bacteria.

Which notable products are in Entasis Therapeutics' pipeline?

Entasis' pipeline includes sulbactam-durlobactam, zoliflodacin, ETX0462, and ETX0282CPDP.

What is the significance of the Cantor Fitzgerald Virtual Global Healthcare Conference for ETTX?

The conference provides a platform for ETTX to present its developments and engage with investors.